Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Emcure"

43 News Found

Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19
News | June 30, 2021

Pharma majors collaborate for clinical trial of Molnupiravir for COVID-19

The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D
Digitisation | May 27, 2021

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D

The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.

Five manufacturers get license to produce Black Fungus drug
News | May 23, 2021

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers

Latest Stories

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Granules India’s facility secures FDA EIR with 'VAI’

Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging